Brief: Acurx Announces Additional Ibezapolstat Ph2b Results In Cdi As Well As Anthrax Susceptibility To Acx-375 Analogues
26/09/2024 12:06
Sept 26 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX ANNOUNCES ADDITIONAL IBEZAPOLSTAT PH2B RESULTS IN
CDI AS
WELL AS ANTHRAX (B. ANTHRACIS) SUSCEPTIBILITY TO ACX-375
ANALOGUES
* ACURX PHARMACEUTICALS INC: NEW ANALYSES EXTEND DATA ON
BENEFICIAL EFFECTS OF IBEZAPOLSTAT ON GUT MICROBIOME
* ACURX PHARMACEUTICALS : CONFIRMED IBEZAPOLSTAT'S FAVORABLE
PHARMACOKINETICS SHOWING LOW SYSTEMIC EXPOSURE AND HIGH COLONIC
CONCENTRATIONS
Source text for Eikon: ID:nPn7Gkfksa
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsBrief: Acurx Pharmaceuticals Receives FDA Conditional Acceptance
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Acurx Pharmaceuticals Q2 loss widens on higher R&D costs
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program